Cargando…

BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy

Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sancho, Mónica, Orzáez, Mar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Author’s Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849717/ https://www.ncbi.nlm.nih.gov/pubmed/33553610 http://dx.doi.org/10.1080/23723556.2020.1859918

Ejemplares similares

Timed degradation of Mcl-1 controls mitotic cell death
por: Clarke, Paul R., et al.
Publicado: (2018)

Understanding MCL1: from cellular function and regulation to pharmacological inhibition
por: Sancho, Mónica, et al.
Publicado: (2021)

The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma
por: Horton, Jaime S, et al.
Publicado: (2014)

BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
por: Cirillo, Luca, et al.
Publicado: (2016)

Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
por: Rossig, Claudia
Publicado: (2012)

DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy
por: Cheng, Xiang, et al.
Publicado: (2020)

Battling the two-headed dragon of prostate cancer targeted therapy
por: Wilkinson, Scott, et al.
Publicado: (2020)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

ImmTACs: Novel bi-specific agents for targeted cancer therapy
por: Oates, Joanne, et al.
Publicado: (2013)

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers
por: Lebret, Thierry, et al.
Publicado: (2015)

Sustaining the spindle assembly checkpoint to improve cancer therapy
por: Visconti, Roberta, et al.
Publicado: (2015)

GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015)

Immunological targeting of cytomegalovirus for glioblastoma therapy
por: Nair, Smita K, et al.
Publicado: (2014)

Consequences of the combined loss of BOK and BAK or BOK and BAX
por: Ke, F, et al.
Publicado: (2013)

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Complexities of pharmacogenomic interactions in cancer
por: Khanna, Kum Kum, et al.
Publicado: (2020)

SAMHD1 is a barrier to antimetabolite-based cancer therapies
por: Rudd, Sean G., et al.
Publicado: (2017)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Targeting SIRPα in cancer
por: Ho, Jenny M., et al.
Publicado: (2013)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Cytomegalovirus infection in brain tumors: A potential new target for therapy?
por: Söderberg-Nauclér, Cecilia, et al.
Publicado: (2012)

Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
por: Cavnar, Michael J, et al.
Publicado: (2014)

Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy
por: Orellana, Laura
Publicado: (2019)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Author Correction: Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
por: Troiani, Martina, et al.
Publicado: (2023)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
por: Xu, Lihong, et al.
Publicado: (2014)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

The adenosinergic system in cancer: Key therapeutic target
por: Sorrentino, Rosalinda, et al.
Publicado: (2013)

COBRA methods and metabolic drug targets in cancer
por: Apaolaza, Iñigo, et al.
Publicado: (2017)

Targeting endosomal pH for cancer chemotherapy
por: Lucien, Fabrice, et al.
Publicado: (2018)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
por: Vigneron, Nathalie, et al.
Publicado: (2015)

The BARD1/HP1 interaction: Another clue to heterochromatin involvement in homologous recombination
por: Fukuda, Takayo, et al.
Publicado: (2015)

Tuning protein synthesis for cancer therapy
por: Knight, John R. P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2d3bfgeaa61gs2uqag5phcnr3k